Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria

Phase 3 Completed 50 enrolled Brigham and Women's Hospital

Treatment

Summary

OBJECTIVES: I. Determine the long-term efficacy and safety of L-cysteine in the prevention photosensitivity in patients with erythropoietic protoporphyria.

Timeline

Start: 1996-05
Primary completion: —
Completion: 2001-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	L-cysteine	Unknown	—	Oral

Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria

Summary

Timeline

Drugs

Indications